The role of the tumor microenvironment in regulating angiogenesis

Cold Spring Harbor Perspectives in Medicine

Volumn 2, Issue 12, 2012, Pages

  Watnick, Randolph S ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5' NUCLEOTIDASE; CD34 ANTIGEN; CELL NUCLEUS RECEPTOR; CHEMOKINE RECEPTOR CXCR4; ENDOGLIN; EPIDERMAL GROWTH FACTOR; ESTROGEN RECEPTOR; FIBROBLAST GROWTH FACTOR 2; GELATINASE B; HERMES ANTIGEN; INTERLEUKIN 8; MATRIX METALLOPROTEINASE; MICROSOMAL AMINOPEPTIDASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MONOCYTE CHEMOTACTIC PROTEIN 1; PLATELET DERIVED GROWTH FACTOR; SCATTER FACTOR; SMOOTH MUSCLE ACTIN; SPHINGOSINE 1 PHOSPHATE; STROMAL CELL DERIVED FACTOR 1; THROMBOSPONDIN 1; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN; CELL RECEPTOR; HORMONE; VASCULOTROPIN A;

ANGIOGENESIS; ARTICLE; BREAST CANCER; CARCINOGENICITY; CELLULAR STRESS SIGNAL; EPITHELIUM TUMOR; EXTRACELLULAR MATRIX; FIBROBLAST; GENE EXPRESSION REGULATION; HUMAN; MACROPHAGE; MAST CELL; MESENCHYMAL STEM CELL; NEUTROPHIL; PARACRINE SIGNALING; PHENOTYPE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STROMA; STROMA CELL; TUMOR GROWTH; TUMOR INVASION; TUMOR MICROENVIRONMENT; TUMOR XENOGRAFT; BONE MARROW CELL; CELL COMMUNICATION; CELL TRANSFORMATION; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; VASCULARIZATION;

BONE MARROW CELLS; CELL COMMUNICATION; CELL TRANSFORMATION, NEOPLASTIC; FIBROBLAST GROWTH FACTOR 2; FIBROBLASTS; HORMONES; HUMANS; MATRIX METALLOPROTEINASES; NEOPLASM INVASIVENESS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, CYTOPLASMIC AND NUCLEAR; STROMAL CELLS; TUMOR MICROENVIRONMENT; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84877264330     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a006676     Document Type: Article

References (185)

1. Abraham JA, Mergia A, Whang JL, Tumolo A, Friedman J, Hjerrild KA, Gospodarowicz D, Fiddes JC. 1986. Nucleotide sequence of a bovine clone encoding the angiogenic protein, basic fibroblast growth factor. Science 233: 545-548.
2. Ai S, Cheng XW, Inoue A, Nakamura K, Okumura K, Iguchi A, Murohara T, Kuzuya M. 2007. Angiogenic activity of bFGF and VEGF suppressed by proteolytic cleavage by neutrophil elastase. Biochem Biophys Res Commun 364: 395-401.
3. Akiyama H, Tanaka T, Maeno T, Kanai H, Kimura Y, Kishi S, Kurabayashi M. 2002. Induction of VEGF gene expression by retinoic acid through Sp1-binding sites in retinoblastoma Y79 cells. Invest Ophthalmol Vis Sci 43: 1367-1374.
4. Aljada A, O'Connor L, Fu YY, Mousa SA. 2008. PPAR γ ligands, rosiglitazone and pioglitazone, inhibit bFGF-and VEGF-mediated angiogenesis. Angiogenesis 11: 361-367.
5. Baird A, Durkin T. 1986. Inhibition of endothelial cell proliferation by type beta-transforming growth factor: Interactions with acidic and basic fibroblast growth factors. Biochem Biophys Res Commun 138: 476-482.
6. Balkwill F, Mantovani A. 2001. Inflammation and cancer: Back to Virchow?Lancet 357: 539-545.
7. Balkwill F, Charles KA, Mantovani A. 2005. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 7: 211-217.
8. Basset P, Bellocq JP, Wolf C, Stoll I, Hutin P, Limacher JM, Podhajcer OL, Chenard MP, Rio MC, Chambon P. 1990. A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas. Nature 348: 699-704.
9. Basset P, Wolf C, Rouyer N, Bellocq JP, Rio MC, Chambon P. 1994. Stromelysin-3 in stromal tissue as a control factor in breast cancer behavior. Cancer 74: 1045-1049.
10. Beckermann BM, Kallifatidis G, Groth A, Frommhold D, Apel A, Mattern J, Salnikov AV, Moldenhauer G, Wagner W, Diehlmann A, et al. 2008. VEGF expression by mesenchymal stem cells contributes to angiogenesis in pancreatic carcinoma. Br J Cancer 99: 622-631.
11. Bellocq A, Antoine M, Flahault A, Philippe C, Crestani B, Bernaudin JF, MayaudC, Milleron B, Baud L, Cadranel J. 1998. Neutrophil alveolitis in bronchioloalveolar carcinoma: Induction by tumor-derived interleukin-8 and relation to clinical outcome. Am J Pathol 152: 83-92.
12. Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K, Tanzawa K, Thorpe P, Itohara S, Werb Z, et al. 2000a. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2: 737-744.
13. Bertin N, Clezardin P, Kubiak R, Frappart L. 1997. Thrombospondin-1 and-2 messenger RNA expression in normal, benign, and neoplastic human breast tissues: Correlation with prognostic factors, tumor angiogenesis, and fibroblastic desmoplasia. Cancer Res 57: 396-399.
14. Birnbaum T, Roider J, Schankin CJ, Padovan CS, Schichor C, Goldbrunner R, Straube A. 2007. Malignant gliomas actively recruit bone marrow stromal cells by secreting angiogenic cytokines. J Neurooncol 83: 241-247.
15. Brogi E, Wu T, Namiki A, Isner JM. 1994. Indirect angiogenic cytokines upregulate VEGF and bFGF gene expression in vascular smooth muscle cells, whereas hypoxia upregulates VEGF expression only. Circulation 90: 649-652.
16. Brown LF, Guidi AJ, Schnitt SJ, Van De Water L, Iruela Arispe ML, Yeo TK, Tognazzi K, Dvorak HF. 1999. Vascular stroma formation in carcinoma in situ, invasive carcinoma, and metastatic carcinoma of the breast. Clin Cancer Res 5: 1041-1056.
17. Brown EB, Boucher Y, Nasser S, Jain RK. 2004. Measurement of macromolecular diffusion coefficients in human tumors. Microvasc Res 67: 231-236.
18. Brunner A, Mayerl C, Tzankov A, Verdorfer I, Tschorner I, Rogatsch H, Mikuz G. 2004. Prognostic significance of tenascin-C expression in superficial and invasive bladder cancer. J Clin Pathol 57: 927-931.
19. Camps JL, Chang SM, Hsu TC, Freeman MR, Hong SJ, Zhau HE, von EschenbachAC, Chung LW. 1990. Fibroblast-mediated acceleration of human epithelial tumor growth in vivo. Proc Natl Acad Sci 87: 75-79.
20. Castor CW, Wilson SM, Heiss PR, Seidman JC. 1979. Activation of lung connective tissue cells in vitro. Am Rev Res Dis 120: 101-106.
21. Chambers AF, Matrisian LM. 1997. Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 89: 1260-1270.
22. Chambers AF, Groom AC, MacDonald IC. 2002. Dissemination and growth of cancer cells in metastatic sites. 2: 563-572.
23. Chang HJ, Park JS, Kim MH, Hong MH, Kim KM, Kim SM, Shin BA, Ahn BW, JungYD. 2006. Extracellular signal-regulated kinases and AP-1 mediate the up-regulation of vascular endothelial growth factor by PDGF in human vascular smooth muscle cells. Int J Oncol 28: 135-141.
24. Chiquet-Ehrismann R, Mackie EJ, Pearson CA, Sakakura T. 1986. Tenascin: An extracellular matrix protein involved in tissue interactions during fetal development and oncogenesis. Cell 47: 131-139.
25. Choi TH, Tseng SC. 2001. In vivo and in vitro demonstration of epithelial cell-induced myofibroblast differentiation of keratocytes and an inhibitory effect by amniotic membrane. Cornea 20: 197-204.
26. Chung LW, Davies R. 1996. Prostate epithelial differentiation is dictated by its surrounding stroma. Mol Biol Rep 23: 13-19.
27. Civin CI, Trischmann T, Kadan NS, Davis J, Noga S, Cohen K, Duffy B, Groenewegen I, Wiley J, Law P, et al. 1996. Highly purified CD34-positive cells reconstitute hematopoiesis. J Clin Oncol 14: 2224-2233.
28. Clark RA, Klebanoff SJ. 1975. Neutrophil-mediated tumor cell cytotoxicity: Role of the peroxidase system. J Exp Med 141: 1442-1447.
29. Clayton A, Evans RA, Pettit E, Hallett M, Williams JD, Steadman R. 1998. Cellular activation through the ligation of intercellular adhesion molecule-1. J Cell Sci 111: 443-453.
30. Clezardin P, Frappart L, Clerget M, Pechoux C, Delmas PD. 1993. Expression of thrombospondin (TSP1) and its receptors (CD36 and CD51) in normal, hyperplastic, and neoplastic human breast. Cancer Research 53: 1421-1430.
31. Coffelt SB, Marini FC, Watson K, Zwezdaryk KJ, Dembinski JL, LaMarca HL, Tomchuck SL, Honer zu Bentrup K, Danka ES, Henkle SL, et al. 2009. The pro-inflammatory peptide LL-37 promotes ovarian tumor progression through recruitment of multipotent mesenchymal stromal cells. Proc Natl Acad Sci 106: 3806-3811.
32. Colombel M, Filleur S, Fournier P, Merle C, Guglielmi J, Courtin A, Degeorges A, Serre CM, Bouvier R, Clezardin P, et al. 2005. Androgens repress the expression of the angiogenesis inhibitor thrombospondin-1 in normal and neoplastic prostate. Cancer Res 65: 300-308.
33. Coussens LM, Werb Z. 1996. Matrix metalloproteinases and the development of cancer. Chem Biol 3: 895-904.
34. Coussens LM, Tinkle CL, Hanahan D, Werb Z. 2000. MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 103: 481-490.
35. Coussens LM, Raymond WW, Bergers G, Laig-Webster M, Behrendtsen O, WerbZ, Caughey GH, Hanahan D. 1999. Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes Dev 13: 1382-1397.
36. Crowther M, Brown NJ, Bishop ET, Lewis CE. 2001. Microenvironmental influence on macrophage regulation of angiogenesis in wounds and malignant tumors. J Leukoc Biol 70: 478-490.
37. Cullen KJ, Allison A, Martire I, Ellis M, Singer C. 1992. Insulin-like growth factor expression in breast cancer epithelium and stroma. Breast Cancer Res Treat 22: 21-29.
38. Cunha GR, Bigsby RM, Cooke PS, Sugimura Y. 1985. Stromal-epithelial interactions in adult organs. Cell Differ 17: 137-148.
39. Damert A, Ikeda E, Risau W. 1997. Activator-protein-1 binding potentiates the hypoxia-inducible factor-1-mediated hypoxia-induced transcriptional activation of vascular-endothelial growth factor expression in C6 glioma cells. Biochem J327: 419-423.
40. Dennis JE, Charbord P. 2002. Origin and differentiation of human and murine stroma. Stem Cells 20: 205-214.
41. Di Carlo E, Forni G, Lollini P, Colombo MP, Modesti A, Musiani P. 2001. The intriguing role of polymorphonuclear neutrophils in antitumor reactions. Blood 97: 339-345.
42. Dimanche-Boitrel MT, Vakaet L Jr., Pujuguet P, Chauffert B, Martin MS, Hammann A, Van Roy F, Mareel M, Martin F. 1994. In vivo and in vitro invasiveness of a rat colon-cancer cell line maintaining E-cadherin expression: An enhancing role of tumor-associated myofibroblasts. Int J Cancer 56: 512-521.
43. Dionne CA, Crumley G, Bellot F, Kaplow JM, Searfoss G, Ruta M, Burgess WH, Jaye M, Schlessinger J. 1990. Cloning and expression of two distinct high-affinity receptors cross-reacting with acidic and basic fibroblast growth factors. EMBO J 9: 2685-2692.
44. Dolberg DS, Hollingsworth R, Hertle M, Bissell MJ. 1985. Wounding and its role in RSV-mediated tumor formation. Science 230: 676-678.
45. Dong J, Grunstein J, Tejada M, Peale F, Frantz G, Liang WC, Bai W, Yu L, Kowalski J, Liang X, et al. 2004. VEGF-null cells require PDGFR α signaling-mediated stromal fibroblast recruitment for tumorigenesis. EMBO J 23: 2800-2810.
46. Dong Z, Kumar R, Yang X, Fidler IJ. 1997. Macrophage-derived metalloelastase is responsible for the generation of angiostatin in Lewis lung carcinoma. Cell 88: 801-810.
47. Dong Z, Yoneda J, Kumar R, Fidler IJ. 1998. Angiostatin-mediated suppression of cancer metastases by primary neoplasms engineered to produce granulocyte/macrophage colony-stimulating factor. J Exp Med 188: 755-763.
48. Donjacour AA, Cunha GR. 1991. Stromal regulation of epithelial function. Cancer Treat Res 53: 335-364.
49. Durning P, Schor SL, Sellwood RA. 1984. Fibroblasts from patients with breast cancer show abnormal migratory behaviour in vitro. Lancet 2: 890-892.
50. Dwyer RM, Potter-Beirne SM, Harrington KA, Lowery AJ, Hennessy E, MurphyJM, Barry FP, O'Brien T, Kerin MJ. 2007. Monocyte chemotactic protein-1 secreted by primary breast tumors stimulates migration of mesenchymal stem cells. Clin Cancer Res 13: 5020-5027.
51. Elenbaas B, Weinberg RA. 2001. Heterotypic signaling between epithelial tumor cells and fibroblasts in carcinoma formation. Exp Cell Res 264: 169-184.
52. Ellis MJ, Singer C, Hornby A, Rasmussen A, Cullen KJ. 1994. Insulin-like growth factor mediated stromal-epithelial interactions in human breast cancer. Breast Cancer Res Treat 31: 249-261.
53. Engel G, Heselmeyer K, Auer G, Backdahl M, Eriksson E, Linder S. 1994. Correlation between stromelysin-3 mRNA level and outcome of human breast cancer. Int J Cancer 58: 830-835.
54. Falanga V, Qian SW, Danielpour D, Katz MH, Roberts AB, Sporn MB. 1991. Hypoxia upregulates the synthesis of TGF-beta 1 by human dermal fibroblasts. J Invest Dermatol 97: 634-637.
55. Filleur S, Volpert OV, Degeorges A, Voland C, Reiher F, Clezardin P, Bouck N, Cabon F. 2001. In vivo mechanisms by which tumors producing thrombospondin 1 bypass its inhibitory effects. Genes Dev 15: 1373-1382.
56. Folkman J, Klagsbrun M. 1987. Angiogenic factors. Science 235: 442-447.
57. Frater-Schroder M, Muller G, Birchmeier W, Bohlen P. 1986. Transforming growth factor-β inhibits endothelial cell proliferation. Biochem Biophys Res Commun 137: 295-302.
58. Friedman AD. 2002. Transcriptional regulation of granulocyte and monocyte development. Oncogene 21: 3377-3390.
59. Fukumura D, Xavier R, Sugiura T, Chen Y, Park EC, Lu N, Selig M, Nielsen G, Taksir T, Jain RK, et al. 1998. Tumor induction of VEGF promoter activity in stromal cells. Cell 94: 715-725.
60. Gabbiani G. 2003. The myofibroblast in wound healing and fibrocontractive diseases. J Pathol 200: 500-503.
61. Gaudry M, Bregerie O, Andrieu V, El Benna J, Pocidalo MA, Hakim J. 1997. Intracellular pool of vascular endothelial growth factor in human neutrophils. Blood 90: 4153-4161.
62. Gerber HP, Kowalski J, Sherman D, Eberhard DA, Ferrara N. 2000. Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor. Cancer Res 60: 6253-6258.
63. Gleave M, Hsieh JT, Gao CA, von Eschenbach AC, Chung LW. 1991. Acceleration of human prostate cancer growth in vivo by factors produced by prostate and bone fibroblasts. Cancer Res 51: 3753-3761.
64. Goerdt S, Orfanos CE. 1999. Other functions, other genes: Alternative activation of antigen-presenting cells. Immunity 10: 137-142.
65. Goldsmith KT, Gammon RB, Garver RI Jr. 1991. Modulation of bFGF in lung fibroblasts by TGF-β and PDGF. Am J Physiol 261: L378-L385.
66. Gordon S. 2003. Alternative activation of macrophages. Nat Rev Immunol 3: 23-35.
67. Grey AM, Schor AM, Rushton G, Ellis I, Schor SL. 1989. Purification of the migration stimulating factor produced by fetal and breast cancer patient fibroblasts. Proc Natl Acad Sci 86: 2438-2442.
68. Gruber BL, Marchese MJ, Kew RR. 1994. Transforming growth factor-β 1 mediates mast cell chemotaxis. J Immunol 152: 5860-5867.
69. Gruber BL, Marchese MJ, Kew R. 1995. Angiogenic factors stimulate mast-cell migration. Blood 86: 2488-2493.
70. Grum-Schwensen B, Klingelhofer J, Berg CH, El-Naaman C, Grigorian M, Lukanidin E, Ambartsumian N. 2005. Suppression of tumor development and metastasis formation in mice lacking the S100A4(mts1) gene. Cancer Res 65: 3772-3780.
71. Guddo F, Fontanini G, Reina C, Vignola AM, Angeletti A, Bonsignore G. 1999. The expression of basic fibroblast growth factor (bFGF) in tumor-associated stromal cells and vessels is inversely correlated with non-small cell lung cancer progression. Hum Pathol 30: 788-794.
72. Gupta PB, Proia D, Cingoz O, Weremowicz J, Naber SP, Weinberg RA, Kuperwasser C. 2007. Systemic stromal effects of estrogen promote the growth of estrogen receptor-negative cancers. Cancer Res 67: 2062-2071.
73. Hall B, Andreeff M, Marini F. 2007. The participation of mesenchymal stem cells in tumor stroma formation and their application as targeted-gene delivery vehicles. Handb Exp Pharmacol 180: 263-283.
74. Han J, Hajjar DP, Tauras JM, Feng J, Gotto AM Jr., Nicholson AC. 2000. Transforming growth factor-beta1 (TGF-β1) and TGF-β2 decrease expression of CD36, the type B scavenger receptor, through mitogen-activated protein kinase phosphorylation of peroxisome proliferator-activated receptor-gamma. J Biol Chem 275: 1241-1246.
75. Hanahan D. 1985. Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. Nature 315: 115-122.
76. Hanahan D, Folkman J. 1996. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86: 353-364.
77. Hanahan D, Weinberg RA. 2000. The hallmarks of cancer. Cell 100: 57-70.
78. Henshall SM, Quinn DI, Lee CS, Head DR, Golovsky D, Brenner PC, Delprado W, Stricker PD, Grygiel JJ, Sutherland RL. 2001. Altered expression of androgen receptor in the malignant epithelium and adjacent stroma is associated with early relapse in prostate cancer. Cancer Res 61: 423-427.
79. Heppner KJ, Matrisian LM, Jensen RA, Rodgers WH. 1996. Expression of most matrix metalloproteinase family members in breast cancer represents a tumor-induced host response. Am J Pathol 149: 273-282.
80. Hom YK, Young P, Wiesen JF, Miettinen PJ, Derynck R, Werb Z, Cunha GR. 1998. Uterine and vaginal organ growth requires epidermal growth factor receptor signaling from stroma. Endocrinology 139: 913-921.
81. Hoodless PA, Haerry T, Abdollah S, Stapleton M, O'Connor MB, Attisano L, Wrana JL. 1996. MADR1, a MAD-related protein that functions in BMP2 signaling pathways. Cell 85: 489-500.
82. Huang S, Van Arsdall M, Tedjarati S, McCarty M, Wu W, Langley R, Fidler IJ. 2002. Contributions of stromal metalloproteinase-9 to angiogenesis and growth of human ovarian carcinoma in mice. J Natl Cancer Inst 94: 1134-1142.
83. Inaguma Y, Kusakabe M, Mackie EJ, Pearson CA, Chiquet-Ehrismann R, Sakakura T. 1988. Epithelial induction of stromal tenascin in the mouse mammary gland: From embryogenesis to carcinogenesis. Dev Biol 128: 245-255.
84. Jin L, Fuchs A, Schnitt SJ, Yao Y, Joseph A, Lamszus K, Park M, Goldberg ID, Rosen EM. 1997. Expression of scatter factor and c-met receptor in benign and malignant breast tissue. Cancer 79: 749-760.
85. Kaipainen A, Kieran MW, Huang S, Butterfield C, Bielenberg D, Mostoslavsky G, Mulligan R, Folkman J, Panigrahy D. 2007. PPARα deficiency in inflammatory cells suppresses tumor growth. PLoS ONE 2: e260.
86. Kalas W, Yu JL, Milsom C, Rosenfeld J, Benezra R, Bornstein P, Rak J. 2005. Oncogenes and angiogenesis: Down-regulation of thrombospondin-1 in normal fibroblasts exposed to factors from cancer cells harboring mutant ras. Cancer Res 65: 8878-8886.
87. Kang SY, Halvorsen OJ, Gravdal K, Bhattacharya N, Lee JM, Liu NW, Johnston BT, Johnston AB, Haukaas SA, Aamodt K, et al. 2009. Prosaposin inhibits tumor metastasis via paracrine and endocrine stimulation of stromal p53 and Tsp-1. Proc Natl Acad Sci 106: 12115-12120.
88. Kanwar VS, Cairo MS. 1993. Neonatal neutrophil maturation, kinetics, and function. In The neutrophil (ed. Abramson JS, Wheeler JG), pp. 1-16. Oxford University Press, New York.
89. Kidd S, Spaeth E, Klopp A, Andreeff M, Hall B, Marini FC. 2008. The (in)auspicious role of mesenchymal stromal cells in cancer: Be it friend or foe. Cytotherapy 10: 657-667.
90. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N. 1993. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362: 841-844.
91. +, and expresses aminopeptidase N (CD13). Blood 94: 2333-2342.
92. Klagsbrun M, Sasse J, Sullivan R, Smith JA. 1986. Human tumor cells synthesize an endothelial cell growth factor that is structurally related to basic fibroblast growth factor. Proc Natl Acad Sci 83: 2448-2452.
93. Kopelovich L. 1982. Genetic predisposition to cancer in man: In vitro studies. Int Rev Cytol 77: 63-88.
94. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. 1989. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246: 1306-1309.
95. Liu F, Hata A, Baker JC, Doody J, Carcamo J, Harland RM, Massague J. 1996. A human Mad protein acting as a BMP-regulated transcriptional activator. Nature 381: 620-623.
96. Lochter A, Galosy S, Muschler J, Freedman N, Werb Z, Bissell MJ. 1997. Matrix metalloproteinase stromelysin-1 triggers a cascade of molecular alterations that leads to stable epithelial-to-mesenchymal conversion and a premalignant phenotype in mammary epithelial cells. J Cell Biol 139: 1861-1872.
97. Lochter A, Sternlicht MD, Werb Z, Bissell MJ. 1998. The significance of matrix metalloproteinases during early stages of tumor progression. Ann NY Acad Sci 857: 180-193.
98. Lyden D, Hattori K, Dias S, Costa C, Blaikie P, Butros L, Chadburn A, Heissig B, Marks W, Witte L, et al. 2001. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 7: 1194-1201.
99. Mackie EJ, Chiquet-Ehrismann R, Pearson CA, Inaguma Y, Taya K, Kawarada Y, Sakakura T. 1987. Tenascin is a stromal marker for epithelial malignancy in the mammary gland. Proc Natl Acad Sci 84: 4621-4625.
100. Majack RA, Cook SC, Bornstein P. 1985. Platelet-derived growth factor and heparin-like glycosaminoglycans regulate thrombospondin synthesis and deposition in the matrix by smooth muscle cells. J Cell Biol 101: 1059-1070.
101. Majack RA, Mildbrandt J, Dixit VM. 1987. Induction of thrombospondin messenger RNA levels occurs as an immediate primary response to platelet-derived growth factor. J Biol Chem 262: 8821-8825.
102. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. 2002. Macrophage polarization: Tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 23: 549-555.
103. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. 2004. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 25: 677-686.
104. Masson R, Lefebvre O, Noel A, Fahime ME, Chenard MP, Wendling C, Kebers F, LeMeur M, Dierich A, Foidart JM, et al. 1998. In vivo evidence that the stromelysin-3 metalloproteinase contributes in a paracrine manner to epithelial cell malignancy. J Cell Biol 140: 1535-1541.
105. Matrisian LM. 1990. Metalloproteinases and their inhibitors in matrix remodeling. Trends Genet 6: 121-125.
106. McCawley LJ, Matrisian LM. 2000. Matrix metalloproteinases: Multifunctional contributors to tumor progression. Mol Med Today 6: 149-156.
107. Mentzel T, Brown LF, Dvorak HF, Kuhnen C, Stiller KJ, Katenkamp D, FletcherCD. 2001. The association between tumour progression and vascularity in myxofibrosarcoma and myxoid/round cell liposarcoma. Virchows Arch 438: 13-22.
108. Mhawech-Fauceglia P, Kaya G, Sauter G, McKee T, Donze O, Schwaller J, HuardB. 2006. The source of APRIL up-regulation in human solid tumor lesions. J Leukoc Biol 80: 697-704.
109. Montesano R, Schaller G, Orci L. 1991. Induction of epithelial tubular morphogenesis in vitro by fibroblast-derived soluble factors. Cell 66: 697-711.
110. Mosser DM. 2003. The many faces of macrophage activation. J Leukoc Biol 73: 209-212.
111. Mueller MM, Fusenig NE. 2002. Tumor-stroma interactions directing phenotype and progression of epithelial skin tumor cells. Differentiation 70: 486-497.
112. Murphy-Ullrich JE, Schultz-Cherry S, Hook M. 1992. Transforming growth factor-β complexes with thrombospondin. Mol Biol Cell 3: 181-188.
113. Nakagawa T, Li JH, Garcia G, Mu W, Piek E, Bottinger EP, Chen Y, Zhu HJ, KangDH, Schreiner GF, et al. 2004. TGF-β induces proangiogenic and antiangiogenic factors via parallel but distinct Smad pathways. Kidney Int 66: 605-613.
114. Netti PA, Berk DA, Swartz MA, Grodzinsky AJ, Jain RK. 2000. Role of extracellular matrix assembly in interstitial transport in solid tumors. Cancer Res 60: 2497-2503.
115. Newell KJ, Witty JP, Rodgers WH, Matrisian LM. 1994. Expression and localization of matrix-degrading metalloproteinases during colorectal tumorigenesis. Mol Carcinog 10: 199-206.
116. Nielsen BS, Timshel S, Kjeldsen L, Sehested M, Pyke C, Borregaard N, Dano K. 1996. 92 kDa type IV collagenase (MMP-9) is expressed in neutrophils and macrophages but not in malignant epithelial cells in human colon cancer. Int J Cancer 65: 57-62.
117. Noel A, De Pauw-Gillet MC, Purnell G, Nusgens B, Lapiere CM, Foidart JM. 1993. Enhancement of tumorigenicity of human breast adenocarcinoma cells in nude mice by matrigel and fibroblasts. Br J Cancer 68: 909-915.
118. Noel A, Hajitou A, L'Hoir C, Maquoi E, Baramova E, Lewalle JM, Remacle A, Kebers F, Brown P, Calberg-Bacq CM, et al. 1998. Inhibition of stromal matrix metalloproteases: Effects on breast-tumor promotion by fibroblasts. Int J Cancer 76: 267-273.
119. Normanno N, Kim N, Wen D, Smith K, Harris AL, Plowman G, Colletta G, Ciardiello F, Salomon DS. 1995. Expression of messenger RNA for amphiregulin, heregulin, and cripto-1, three new members of the epidermal growth factor family, in human breast carcinomas. Breast Cancer Res Treat 35: 293-297.
120. Norrby K. 2002. Mast cells and angiogenesis. APMIS 110: 355-371.
121. Nozawa H, Chiu C, Hanahan D. 2006. Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis. Proc Natl Acad Sci 103: 12493-12498.
122. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH, Folkman J. 1994. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79: 315-328.
123. Olaso E, Santisteban A, Bidaurrazaga J, Gressner AM, Rosenbaum J, Vidal-Vanaclocha F. 1997. Tumor-dependent activation of rodent hepatic stellate cells during experimental melanoma metastasis. Hepatology Baltimore, Md 26: 634-642.
124. Olaso E, Vidal-Vanaclocha F. 2003. Use of tumor-activated hepatic stellate cell as a target for the preclinical testing of anti-angiogenic drugs against hepatic tumor development. Methods Mol Med 85: 79-86.
125. Olumi AF, Grossfeld GD, Hayward SW, Carroll PR, Tlsty TD, Cunha GR. 1999. Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res 59: 5002-5011.
126. Orimo A, Weinberg RA. 2006. Stromal fibroblasts in cancer: A novel tumor-promoting cell type. Cell Cycle 5: 1597-1601.
127. Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naeem R, Carey VJ, Richardson AL, Weinberg RA. 2005. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 121: 335-348.
128. Panico L, D'Antonio A, Salvatore G, Mezza E, Tortora G, De Laurentiis M, De Placido S, Giordano T, Merino M, Salomon DS, et al. 1996. Differential immunohistochemical detection of transforming growth factor α, amphiregulin and CRIPTO in human normal and malignant breast tissues. Int J Cancer 65: 51-56.
129. Panigrahy D, Kaipainen A, Huang S, Butterfield CE, Barnes CM, Fannon M, Laforme AM, Chaponis DM, Folkman J, Kieran MW. 2008. PPARα agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition. Proc Natl Acad Sci 105: 985-990.
130. Parsonage G, Filer AD, Haworth O, Nash GB, Rainger GE, Salmon M, BuckleyCD. 2005. A stromal address code defined by fibroblasts. Trends Immunol 26: 150-156.
131. Penttinen RP, Kobayashi S, Bornstein P. 1988. Transforming growth factor β increases mRNA for matrix proteins both in the presence and in the absence of changes in mRNA stability. Proc Natl Acad Sci 85: 1105-1108.
132. Pertovaara L, Kaipainen A, Mustonen T, Orpana A, Ferrara N, Saksela O, AlitaloK. 1994. Vascular endothelial growth factor is induced in response to transforming growth factor-β in fibroblastic and epithelial cells. J Biol Chem 269: 6271-6274.
133. Pettaway CA, Pathak S, Greene G, Ramirez E, Wilson MR, Killion JJ, Fidler IJ. 1996. Selection of highly metastatic variants of different human prostatic carcinomas using orthotopic implantation in nude mice. Clin Cancer Res 2: 1627-1636.
134. Picard O, Rolland Y, Poupon MF. 1986. Fibroblast-dependent tumorigenicity of cells in nude mice: Implication for implantation of metastases. Cancer Res 46: 3290-3294.
135. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, MoormanMA, Simonetti DW, Craig S, Marshak DR. 1999. Multilineage potential of adult human mesenchymal stem cells. Science 284: 143-147.
136. Qu Z, Huang X, Ahmadi P, Stenberg P, Liebler JM, Le AC, Planck SR, RosenbaumJT. 1998. Synthesis of basic fibroblast growth factor by murine mast cells. Regulation by transforming growth factor β, tumor necrosis factor α, and stem cell factor. Int Arch Allergy Immunol 115: 47-54.
137. Rak J, Mitsuhashi Y, Bayko L, Filmus J, Shirasawa S, Sasazuki T, Kerbel RS. 1995. Mutant ras oncogenes upregulate VEGF/VPF expression: Implications for induction and inhibition of tumor angiogenesis. Cancer Research 55: 4575-4580.
138. Rak J, Mitsuhashi Y, Sheehan C, Tamir A, Viloria-Petit A, Filmus J, Mansour SJ, Ahn NG, Kerbel RS. 2000. Oncogenes and tumor angiogenesis: Differential modes of vascular endothelial growth factor up-regulation in ras-transformed epithelial cells and fibroblasts. Cancer Res 60: 490-498.
139. Roberts AB, Sporn MB, Assoian RK, Smith JM, Roche NS, Wakefield LM, HeineUI, Liotta LA, Falanga V, Kehrl JH, et al. 1986. Transforming growth factor type β: Rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci 83: 4167-4171.
140. Rodemann HP, Muller GA. 1991. Characterization of human renal fibroblasts in health and disease: II. In vitro growth, differentiation, and collagen synthesis of fibroblasts from kidneys with interstitial fibrosis. Am J Kidney Dis 17: 684-686.
141. Rodriguez-Manzaneque JC, Lane TF, Ortega MA, Hynes RO, Lawler J, Iruela-Arispe ML. 2001. Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor. Proc Natl Acad Sci 98: 12485-12490.
142. Rogelj S, Weinberg RA, Fanning P, Klagsbrun M. 1988. Basic fibroblast growth factor fused to a signal peptide transforms cells. Nature 331: 173-175.
143. Rogelj S, Weinberg RA, Fanning P, Klagsbrun M. 1989. Characterization of tumors produced by signal peptide-basic fibroblast growth factor-transformed cells. J Cell Biochem 39: 13-23.
144. Ronnov-Jessen L, Petersen OW. 1993. Induction of alpha-smooth muscle actin by transforming growth factor-β 1 in quiescent human breast gland fibroblasts. Implications for myofibroblast generation in breast neoplasia. Lab Invest 68: 696-707.
145. Ronnov-Jessen L, Petersen OW, Bissell MJ. 1996. Cellular changes involved in conversion of normal to malignant breast: Importance of the stromal reaction. Physiol Rev 76: 69-125.
146. Sack GH Jr., Levin J, Bell WR. 1977. Trousseau's syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms: Clinical, pathophysiologic, and therapeutic features. Medicine (Balt)56: 1-37.
147. Salcedo R, Wasserman K, Young HA, Grimm MC, Howard OM, Anver MR, Kleinman HK, Murphy WJ, Oppenheim JJ. 1999. Vascular endothelial growth factor and basic fibroblast growth factor induce expression of CXCR4 on human endothelial cells: In vivo neovascularization induced by stromal-derived factor-1α. Am J Pathol 154: 1125-1135.
148. Sappino AP, Skalli O, Jackson B, Schurch W, Gabbiani G. 1988. Smooth-muscle differentiation in stromal cells of malignant and non-malignant breast tissues. Int J Cancer 41: 707-712.
149. Scapini P, Nesi L, Morini M, Tanghetti E, Belleri M, Noonan D, Presta M, AlbiniA, Cassatella MA. 2002. Generation of biologically active angiostatin kringle 1-3 by activated human neutrophils. J Immunol 168: 5798-5804.
150. Schichor C, Birnbaum T, Etminan N, Schnell O, Grau S, Miebach S, Aboody K, Padovan C, Straube A, Tonn JC, et al. 2006. Vascular endothelial growth factor A contributes to glioma-induced migration of human marrow stromal cells (hMSC). Exp Neurol 199: 301-310.
151. Schioppa T, Uranchimeg B, Saccani A, Biswas SK, Doni A, Rapisarda A, Bernasconi S, Saccani S, Nebuloni M, Vago L, et al. 2003. Regulation of the chemokine receptor CXCR4 by hypoxia. J Exp Med 198: 1391-1402.
152. Schor SL, Schor AM, Grey AM, Rushton G. 1988a. Foetal and cancer patient fibroblasts produce an autocrine migration-stimulating factor not made by normal adult cells. J Cell Sci 90: 391-399.
153. Schor SL, Schor AM, Rushton G. 1988b. Fibroblasts from cancer patients display a mixture of both foetal and adult-like phenotypic characteristics. J Cell Sci 90: 401-407.
154. Schultz Cherry S, Murphy Ullrich JE. 1993. Thrombospondin causes activation of latent transforming growth factor-beta secreted by endothelial cells by a novel mechanism. J Cell Biol 122: 923-932.
155. Schultz Cherry S, Lawler J, Murphy Ullrich JE. 1994a. The type 1 repeats of thrombospondin 1 activate latent transforming growth factor-beta. J Biol Chem 269: 26783-26788.
156. Schultz Cherry S, Ribeiro S, Gentry L, Murphy Ullrich JE. 1994b. Thrombospondin binds and activates the small and large forms of latent transforming growth factor-beta in a chemically defined system. J Biol Chem 269: 26775-26782.
157. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. 1983. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219: 983-985.
158. Sengupta K, Banerjee S, Saxena NK, Banerjee SK. 2004. Thombospondin-1 disrupts estrogen-induced endothelial cell proliferation and migration and its expression is suppressed by estradiol. Mol Cancer Res 2: 150-158.
159. Seslar SP, Nakamura T, Byers SW. 1993. Regulation of fibroblast hepatocyte growth factor/scatter factor expression by human breast carcinoma cell lines and peptide growth factors. Cancer Res 53: 1233-1238.
160. Sher A, Pearce E, Kaye P. 2003. Shaping the immune response to parasites: Role of dendritic cells. Curr Opin Immunol 15: 421-429.
161. Shing Y, Folkman J, Sullivan R, Butterfield C, Murray J, Klagsbrun M. 1984. Heparin affinity: Purification of a tumor-derived capillary endothelial cell growth factor. Science 223: 1296-1299.
162. Soucek L, Lawlor ER, Soto D, Shchors K, Swigart LB, Evan GI. 2007. Mast cells are required for angiogenesis and macroscopic expansion of Myc-induced pancreatic islet tumors. Nat Med 13: 1211-1218.
163. Spaeth E, Klopp A, Dembinski J, Andreeff M, Marini F. 2008. Inflammation and tumor microenvironments: Defining the migratory itinerary of mesenchymal stem cells. Gene Ther 15: 730-738.
164. Steele RW, Steele CR, Pilkington NS Jr., Charlton RK. 1987. Functional capacity of marginated and bone marrow reserve granulocytes. Infect Immun 55: 2359-2363.
165. Streit M, Velasco P, Brown LF, Skobe M, Richard L, Riccardi L, Lawler J, DetmarM. 1999. Overexpression of thrombospondin-1 decreases angiogenesis and inhibits the growth of human cutaneous squamous cell carcinomas. Am J Pathol 155: 441-452.
166. Sun B, Zhang S, Ni C, Zhang D, Liu Y, Zhang W, Zhao X, Zhao C, Shi M. 2005. Correlation between melanoma angiogenesis and the mesenchymal stem cells and endothelial progenitor cells derived from bone marrow. Stem Cells Dev 14: 292-298.
167. Suratt BT, Petty JM, Young SK, Malcolm KC, Lieber JG, Nick JA, Gonzalo JA, Henson PM, Worthen GS. 2004. Role of the CXCR4/SDF-1 chemokine axis in circulating neutrophil homeostasis. Blood 104: 565-571.
168. Suwa T, Hogg JC, English D, Van Eeden SF. 2000. Interleukin-6 induces demargination of intravascular neutrophils and shortens their transit in marrow. Am J Physiol Heart Circ Physiol 279: H2954-2960.
169. Tanaka A, Arai K, Kitamura Y, Matsuda H. 1999. Matrix metalloproteinase-9 production, a newly identified function of mast cell progenitors, is downregulated by c-kit receptor activation. Blood 94: 2390-2395.
170. Tarin D, Croft CB. 1969. Ultrastructural features of wound healing in mouse skin. Journal of anatomy 105: 189-190.
171. Tazzyman S, Lewis CE, Murdoch C. 2009. Neutrophils: Key mediators of tumour angiogenesis. Int J Exp Pathol 90: 222-231.
172. To CT, Tsao MS. 1998. The roles of hepatocyte growth factor/scatter factor and met receptor in human cancers (Review). Oncol Rep 5: 1013-1024.
173. Tomasek JJ, McRae J, Owens GK, Haaksma CJ. 2005. Regulation of α-smooth muscle actin expression in granulation tissue myofibroblasts is dependent on the intronic CArG element and the transforming growth factor-beta1 control element. Am J Pathol 166: 1343-1351.
174. Tsai JC, Goldman CK, Gillespie GY. 1995. Vascular endothelial growth factor in human glioma cell lines: Induced secretion by EGF, PDGF-BB, bFGF. J Neurosurg 82: 864-873.
175. Tsukada T, McNutt MA, Ross R, Gown AM. 1987. HHF35, a muscle actin-specific monoclonal antibody. II. Reactivity in normal, reactive, and neoplastic human tissues. Am J Pathol 127: 389-402.
176. Tuxhorn JA, Ayala GE, Rowley DR. 2001. Reactive stroma in prostate cancer progression. J Urol 166: 2472-2483.
177. Vande Woude GF, Jeffers M, Cortner J, Alvord G, Tsarfaty I, Resau J. 1997. Met-HGF/SF: Tumorigenesis, invasion and metastasis. Ciba Found Symp 212: 119-130; discussion 130-112, 148-154.
178. Watnick R, Cheng YN, Rangarajan A, Ince T, Weinberg RA. 2003. Ras modulates Myc activity to repress thrombospondin-1 expression and increase tumor angiogenesis. Cancer Cell 3: 219-231.
179. Wojta J, Kaun C, Breuss JM, Koshelnick Y, Beckmann R, Hattey E, Mildner M, Weninger W, Nakamura T, Tschachler E, et al. 1999. Hepatocyte growth factor increases expression of vascular endothelial growth factor and plasminogen activator inhibitor-1 in human keratinocytes and the vascular endothelial growth factor receptor flk-1 in human endothelial cells. Lab Invest 79: 427-438.
180. Wolf C, Rouyer N, Lutz Y, Adida C, Loriot M, Bellocq JP, Chambon P, Basset P. 1993. Stromelysin 3 belongs to a subgroup of proteinases expressed in breast carcinoma fibroblastic cells and possibly implicated in tumor progression. Proc Natl Acad Sci 90: 1843-1847.
181. Wong SY, Purdie AT, Han P. 1992. Thrombospondin and other possible related matrix proteins in malignant and benign breast disease. An immunohistochemical study. Am J Path 140: 1473-1482.
182. Xie K. 2001. Interleukin-8 and human cancer biology. Cytokine Growth Factor Rev 12: 375-391.
183. Xiong S, Grijalva R, Zhang L, Nguyen NT, Pisters PW, Pollock RE, Yu D. 2001. Up-regulation of vascular endothelial growth factor in breast cancer cells by the heregulin-β1-activated p38 signaling pathway enhances endothelial cell migration. Cancer Res 61: 1727-1732.
184. Yee D, Paik S, Lebovic GS, Marcus RR, Favoni RE, Cullen KJ, Lippman ME, RosenN. 1989. Analysis of insulin-like growth factor I gene expression in malignancy: Evidence for a paracrine role in human breast cancer. Mol Endocrinol 3: 509-517.
185. Yu Q, Stamenkovic I. 2000. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-β and promotes tumor invasion and angiogenesis. Genes Dev 14: 163-176.